Table 2.
Clinical adverse events and biological abnormalities reported in our cohort of 96 patients.
| Number of patients (%) | |
|---|---|
| Clinical adverse events | |
| Diarrhea | 3 (3%) |
| Muscular pain | 3 (3%) |
| Headache | 4 (4%) |
| Fatigue | 13 (13.5%) |
| Dizziness | 1 (1%) |
| Insomnia | 7 (7%) |
| Biological Abnormalities* | |
| Total serum bilirubin | |
| Grade 1 (>ULN − 1.5 × ULN) | 4 (4%) |
| Grade 2 (>1.5–3.0 × ULN) | 1 (1%) |
| CPK | |
| Grade 1 (>ULN − 2.5 × ULN) | 4 (4%) |
| Grade 2 (>2.5–5 × ULN) | 1 (1%) |
*Grade classification according to “Common Terminology Criteria for Adverse Events v4.0”34 CPK: creatinine phosphokinase, ULN: upper limit of normal range.